NeuroBo Pharmaceuticals Inc (NRBO)
3.80
-0.26
(-6.40%)
USD |
NASDAQ |
May 31, 16:00
3.85
+0.05
(+1.32%)
After-Hours: 20:00
NeuroBo Pharmaceuticals Enterprise Value: 2.655M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 31, 2024 | 2.655M |
May 30, 2024 | 3.930M |
May 29, 2024 | 3.636M |
May 28, 2024 | 4.47M |
May 24, 2024 | 4.274M |
May 23, 2024 | 3.513M |
May 22, 2024 | 5.304M |
May 21, 2024 | 6.482M |
May 20, 2024 | 6.580M |
May 17, 2024 | 6.874M |
May 16, 2024 | 6.580M |
May 15, 2024 | 4.813M |
May 14, 2024 | 4.176M |
May 13, 2024 | 3.783M |
May 10, 2024 | 3.440M |
May 09, 2024 | 3.612M |
May 08, 2024 | 3.293M |
May 07, 2024 | 2.851M |
May 06, 2024 | 2.655M |
May 03, 2024 | 2.557M |
May 02, 2024 | 2.311M |
May 01, 2024 | 2.066M |
April 30, 2024 | -0.0435M |
April 29, 2024 | -0.1416M |
April 26, 2024 | -0.5832M |
Date | Value |
---|---|
April 25, 2024 | -0.9756M |
April 24, 2024 | -0.7794M |
April 23, 2024 | -1.172M |
April 22, 2024 | -0.6813M |
April 19, 2024 | 0.5452M |
April 18, 2024 | 0.8886M |
April 17, 2024 | 0.9868M |
April 16, 2024 | 0.6924M |
April 15, 2024 | 1.330M |
April 12, 2024 | 1.723M |
April 11, 2024 | 1.576M |
April 10, 2024 | 1.477M |
April 09, 2024 | 1.330M |
April 08, 2024 | 3.489M |
April 05, 2024 | 3.047M |
April 04, 2024 | 3.096M |
April 03, 2024 | 3.096M |
April 02, 2024 | 3.293M |
April 01, 2024 | 3.930M |
March 28, 2024 | -2.370M |
March 27, 2024 | -1.143M |
March 26, 2024 | -1.339M |
March 25, 2024 | -0.9222M |
March 22, 2024 | -0.5542M |
March 21, 2024 | 0.0345M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-20.46M
Minimum
Jun 23 2023
454.09M
Maximum
Feb 12 2020
41.13M
Average
6.130M
Median
Aug 01 2019
Enterprise Value Benchmarks
Altimmune Inc | 350.45M |
Vanda Pharmaceuticals Inc | -95.58M |
Viking Therapeutics Inc | 5.907B |
vTv Therapeutics Inc | 10.60M |
Rhythm Pharmaceuticals Inc | 1.974B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -6.714M |
Total Expenses (Quarterly) | 6.881M |
EPS Diluted (Quarterly) | -1.32 |
Earnings Yield | -84.74% |